• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Identification of therapeutic targets and elucidation of the mechanism of development and progression of rare and poor prognosis endometrial cancers

Research Project

Project/Area Number 19K16572
Research Category

Grant-in-Aid for Early-Career Scientists

Allocation TypeMulti-year Fund
Review Section Basic Section 49020:Human pathology-related
Research InstitutionNational Cancer Center Japan

Principal Investigator

Yoshida Hiroshi  国立研究開発法人国立がん研究センター, 中央病院, 医員 (70750751)

Project Period (FY) 2019-04-01 – 2023-03-31
Project Status Completed (Fiscal Year 2022)
Budget Amount *help
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2020: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2019: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Keywords子宮体癌 / 遺伝子解析 / 免疫組織化学染色 / 予後因子 / 治療標的 / 希少がん / 診断病理学 / バイオマーカー / 分子病理分類 / 初期病変 / 子宮体部漿液性癌 / 子宮体部明細胞癌 / 子宮体部癌肉腫
Outline of Research at the Start

本研究の目的は、希少かつ予後不良なタイプの子宮体癌の、発生・進展機序を分子病理学的解析により明らかにし、早期診断や治療標的の同定し、患者の予後改善に貢献することにある。対象は、漿液性癌、明細胞癌、癌肉腫、脱分化癌/未分化癌、神経内分泌癌、grade 3類内膜癌、再発したgrade 1類内膜癌である。これら希少で予後不良な子宮体癌の早期病変に着目し、患者由来試料を用い、分子病理学的異常(遺伝子変異、mRNA発現異常、蛋白発現異常)を解析し、非腫瘍性内膜・浸潤性病変と比較検討することで、発がん・進展過程の基盤となる分子異常を解明する。

Outline of Final Research Achievements

In this study, we characterized the clinicopathologucal factors, prognosis, and genetic abnormalities/protein expression of infrequent but poor prognosis endometrial cancers (grade 3 endometrioid carcinoma, serous carcinoma, carcinosarcoma, dedifferentiated carcinoma, etc.) to identify potential therapeutic targets and early diagnosis of these rare subtypes of endometrial cancers. Among patients with these rare subtypes of endometrial cancer, we have found factors that predict which patients are more likely to recur, molecular abnormalities that may be potential therapeutic targets, and features that may be useful for early diagnosis, which we have published in several papers.

Academic Significance and Societal Importance of the Research Achievements

本研究は、これまで十分に明らかになっていなかった、稀だけれども予後不良な子宮体癌のサブタイプについて、様々な特徴を明らかにすることを目的として実施されました。本研究の成果により、これらのサブタイプの子宮体癌で、どのような患者さんが再発しやすいのか、どのような治療標的となる遺伝子・蛋白レベルの異常があるのか、どのような情報に注目すると早期診断が可能になるのか、といった問いに対して、可能性のあるいくつかの答えを提示し、論文として世界に公表することが出来ました。

Report

(5 results)
  • 2022 Annual Research Report   Final Research Report ( PDF )
  • 2021 Research-status Report
  • 2020 Research-status Report
  • 2019 Research-status Report
  • Research Products

    (10 results)

All 2023 2022 2021

All Journal Article (10 results) (of which Peer Reviewed: 10 results,  Open Access: 4 results)

  • [Journal Article] Utility of molecular subtypes and genetic alterations for evaluating clinical outcomes in 1029 patients with endometrial cancer2023

    • Author(s)
      Asami Y, Kobayshi Kato M, Shiraishi K, Yoshida H
    • Journal Title

      Br J Cancer

      Volume: 128 Issue: 8 Pages: 1582-1591

    • DOI

      10.1038/s41416-023-02203-3

    • Related Report
      2022 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Discordances in expression of human epidermal growth factor receptor 2 between primary and metastatic uterine carcinosarcoma: A proposal for HER2-targeted therapy specimen selection2023

    • Author(s)
      Yoshida Hiroshi、Mizoguchi Chiharu、Saito Ayumi、Kitadai Rui、Yamamoto Kasumi、Nishikawa Tadaaki、Kato Tomoyasu、Yonemori Kan
    • Journal Title

      Annals of Diagnostic Pathology

      Volume: 65 Pages: 152150-152150

    • DOI

      10.1016/j.anndiagpath.2023.152150

    • Related Report
      2022 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Endometrioid Endometrial Carcinoma With NKX3.1 Expression in a Transgender Man: A Case Report2023

    • Author(s)
      Yoshida Hiroshi、Uno Masaya、Ogimoto Keisuke、Kobayashi-Kato Mayumi、Tanase Yasuhito、Ishikawa Mitsuya、Kato Tomoyasu
    • Journal Title

      International Journal of Gynecological Pathology

      Volume: 42 Issue: 3 Pages: 308-314

    • DOI

      10.1097/pgp.0000000000000869

    • Related Report
      2022 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Clinical impact of genetic alterations of CTNNB1 in patients with grade 3 endometrial endometrioid carcinoma2022

    • Author(s)
      Kato MK
    • Journal Title

      Cancer Sci.

      Volume: - Issue: 5 Pages: 1712-1721

    • DOI

      10.1111/cas.15328

    • Related Report
      2022 Annual Research Report 2021 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Loss of ARID1A Expression as a Favorable Prognostic Factor in Early-Stage Grade 3 Endometrioid Endometrial Carcinoma Patients2021

    • Author(s)
      Kato MK
    • Journal Title

      Pathol Oncol Res.

      Volume: 27 Pages: 598550-598550

    • DOI

      10.3389/pore.2021.598550

    • Related Report
      2021 Research-status Report 2020 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Unique prognostic features of grade 3 endometrioid endometrial carcinoma: Findings from 101 consecutive cases at a Japanese tertiary cancer center2021

    • Author(s)
      Kato MK, Yoshida H, Uehara T, Uno M, Ishikawa M, Miyasaka N, Kato T.
    • Journal Title

      Taiwan J Obstet Gynecol .

      Volume: 60(2) Issue: 2 Pages: 238-244

    • DOI

      10.1016/j.tjog.2020.12.005

    • Related Report
      2021 Research-status Report 2020 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Magnetic resonance imaging findings in 11 cases of dedifferentiated endometrial carcinoma of the uterus2021

    • Author(s)
      Kikkawa Nao、Ito Kimiteru、Yoshida Hiroshi、Kato Mayumi Kobayashi、Kubo Yuko、Onishi Yasuyuki、Sugawara Haruto、Kato Tomoyasu、Kusumoto Masahiko
    • Journal Title

      Japanese Journal of Radiology

      Volume: 39 Issue: 5 Pages: 477-486

    • DOI

      10.1007/s11604-020-01084-3

    • NAID

      210000187434

    • Related Report
      2021 Research-status Report 2020 Research-status Report
    • Peer Reviewed
  • [Journal Article] Human epidermal growth factor receptor 2 targeted therapy in endometrial cancer: Clinical and pathological perspectives2021

    • Author(s)
      Saito Ayumi、Yoshida Hiroshi、Nishikawa Tadaaki、Yonemori Kan
    • Journal Title

      World Journal of Clinical Oncology

      Volume: 12 Issue: 10 Pages: 868-881

    • DOI

      10.5306/wjco.v12.i10.868

    • Related Report
      2021 Research-status Report
    • Peer Reviewed
  • [Journal Article] Genetic features of endometrioid-type endometrial carcinoma arising in uterine adenomyosis2021

    • Author(s)
      Yoshida Hiroshi、Asami Yuka、Kobayashi-Kato Mayumi、Tanase Yasuhito、Uno Masaya、Ishikawa Mitsuya、Shiraishi Kouya、Kato Tomoyasu
    • Journal Title

      Virchows Archiv

      Volume: . Issue: 1 Pages: 407-412

    • DOI

      10.1007/s00428-021-03234-y

    • Related Report
      2021 Research-status Report
    • Peer Reviewed
  • [Journal Article] Histopathological features of HER2 overexpression in uterine carcinosarcoma: proposal for requirements in HER2 testing for targeted therapy2021

    • Author(s)
      Yoshida Hiroshi、Nishikawa Tadaaki、Matsumoto Koji、Mori Masahiko、Hirashima Yasuyuki、Takehara Kazuhiro、Ariyoshi Kazuya、Hasegawa Kosei、Yonemori Kan
    • Journal Title

      Virchows Archiv

      Volume: 478 Issue: 6 Pages: 1161-1171

    • DOI

      10.1007/s00428-021-03017-5

    • Related Report
      2021 Research-status Report
    • Peer Reviewed

URL: 

Published: 2019-04-18   Modified: 2024-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi